Aspen Neuroscience's IPO
9,375,000 shares at $15 to $17 (amended S-1 of Oct 26, 2026). No day set yet.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
Once Aspen Neuroscience lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does Aspen Neuroscience do?
“Aspen Neuroscience, Inc. is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.”
| Fact | Aspen Neuroscience |
|---|---|
| Founded | 2018 |
| Incorporated | Delaware, 2018 |
| Headquarters | San Diego, California |
| Employees | 120 full-time, as of June 30, 2026 |
| Website | aspenneuroscience.com |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | Aspen Neuroscience |
|---|---|
| Shares offered | 9,375,000 |
| Price range | $15 to $17 a share |
| Net proceeds the company expects | About $135 million |
| Underwriters' option | 1,406,250 more shares |
| Underwriters | Leerink Partners, UBS, Piper Sandler, Stifel, and Oppenheimer |
| Exchange | Nasdaq Global Select Market, as ASPE (applied to list) |
| Shares outstanding after | 29,078,600 |
| Market cap at the midpoint | $465 million |
What the filing says about its money
| Fact | Aspen Neuroscience |
|---|---|
| Revenue | None from product sales yet |
| Net loss | $62.1 million, year to December 31, 2025 |
| Cash | $72.4 million, as of June 30, 2026 |
| Last preferred stock | Series C preferred |
| Raised before the IPO | $340 million in private financings |
What risks does Aspen Neuroscience name first?
- “We are a clinical-stage regenerative medicine biotechnology company with a limited operating history and no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of product candidates and the prospects for our future viability.”
- “We have incurred substantial operating losses since our inception and expect to incur substantial losses for the foreseeable future.”
- “Our financial condition raises substantial doubt as to our ability to continue as a going concern.”
Every date of Aspen Neuroscience's IPO
| What | Day |
|---|---|
| Registration filed | Oct 9, 2026 |
| Price range set | Oct 26, 2026 |
| Lock-up | 180 days |
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 | |
| $5 |
Aspen Neuroscience IPO questions
When is Aspen Neuroscience's IPO?
9,375,000 shares at $15 to $17 (amended S-1 of Oct 26, 2026). No day set yet.
What is Aspen Neuroscience's IPO price?
Aspen Neuroscience set a range of $15 to $17 a share in its amended S-1 of Oct 26, 2026. The final price is set the evening before it lists.
How many shares is Aspen Neuroscience selling?
9,375,000 shares, and the underwriters may buy 1,406,250 more, per its amended S-1.
Who are the underwriters?
Leerink Partners, UBS, Piper Sandler, Stifel, and Oppenheimer, as the prospectus's cover names them.
When does the lock-up end?
Its prospectus sets a lock-up of 180 days; the day it ends is read from its final prospectus once it lists.
Does Breakaway rate Aspen Neuroscience?
Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.
Can Breakaway say where Aspen Neuroscience's price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Once Aspen Neuroscience lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.